ANDA 40014, held by Hikma. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 40014 (Lidocaine Hydrochloride), held by Hikma, was first approved by FDA on Jul 10, 1995, with 5 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Lidocaine Hydrochloride Oral Topical Solution, USP (Viscous) 2% is indicated for the production of topical anesthesia of irritated or inflamed mucous membranes of the mouth and pharynx. It is also useful for reducing gagging during the taking of X-ray pictures and dental impressions.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 10, 1995 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lidocaine Hydrochloride2% · solution;oral | Lidocaine Hydrochloride | Discontinued |
| Nov 2, 2018 | Supplement 8Labeling · Standard review | Approved | None posted |
| Nov 1, 2018 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 2, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Mar 24, 2015 | Supplement 4Manufacturing | Approved | None posted |
| Aug 25, 1997 | Supplement 1Manufacturing | Approved | None posted |
| Jul 10, 1995 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters